Dr. Cody Orahoske is a clinical chemist and technical director with a strong foundation in clinical chemistry, toxicology, mass spectrometry and laboratory management. He earned his PhD in Clinical Chemistry from Cleveland State University and a Clinical Chemistry Postdoctoral Fellowship at the University of California, San Francisco. His academic background also includes dual undergraduate degrees in Chemistry and Business Economics, equipping him with a unique blend of scientific and operational insight. Throughout his career, Dr. Orahoske has demonstrated a commitment to advancing the role of the clinical laboratory in healthcare. He has led high-complexity testing in automated and special chemistry, developed and validated LC-MS/MS assays, and contributed to emergency toxicology casework. His translational research has focused on emerging drugs of abuse, and he has authored numerous peer-reviewed publications in journals such as The Journal of Applied Laboratory Medicine, Bioorganic & Medicinal Chemistry, and ACS Infectious Diseases. Beyond the bench, Dr. Orahoske has built informatics tools and led test utilization studies, combining clinical, operational, and financial perspectives to improve patient care. His work reflects a broader vision: to bridge clinical service, translational science, and operational leadership. He aims to ensure that laboratory medicine not only delivers accurate and timely diagnostics but also drives innovation and efficiency across healthcare systems.
Dr. Orahoske’s contributions have been recognized with multiple honors, including the MSACL Young Investigator Educational Grant (awarded in 2023, 2024, and 2025), the ACPLS Paul E. Strandjord Young Investigator Award, and several institutional awards for research and leadership. His career trajectory reflects a deep dedication to both scientific excellence and the practical application of laboratory science in improving patient outcomes.